| sess_SDA-2026-04-11- | The debate highlighted that long-term CRISPR expression triggers immune response | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-11-gap-debate-20260410-112625-c44578b5 |
| sess_SDA-2026-04-11- | The debate highlighted that TREM2 therapeutic targeting remains contested across | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-11-gap-debate-20260410-112636-141592ba |
| sess_SDA-2026-04-11- | The debate transcript shows incomplete analysis where the Theorist reached maxim | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-11-gap-debate-20260410-112649-f72c1ba2 |
| sess_SDA-2026-04-11- | The debate aimed to cross-reference Allen Aging Mouse Brain Atlas data with huma | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-11-gap-debate-20260410-112700-e284319e |
| sess_SDA-2026-04-11- | The debate was initiated to analyze cell-type-specific vulnerability using SEA-A | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-11-gap-debate-20260410-112706-7f5a9480 |
| sess_SDA-2026-04-11- | The debate initiated investigation into white matter aging and myelin changes bu | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-11-gap-debate-20260410-112718-0b78e493 |
| sess_SDA-2026-04-11- | The debate failed to produce any actual hypotheses despite this being the core r | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-11-gap-debate-20260410-112725-4369698d |
| sess_SDA-2026-04-12- | The debate was structured to identify aging-neurodegeneration mechanisms using A | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-12-gap-debate-20260410-112741-51d89235 |
| sess_SDA-2026-04-12- | The debate transcript shows incomplete information exchange, suggesting this fun | 0.49 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-12-gap-debate-20260410-112747-72269a36 |
| sess_SDA-2026-04-12- | The debate highlighted the bidirectional relationship between sleep and neurodeg | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-12-gap-debate-20260410-112754-fc3e63c8 |
| sess_SDA-2026-04-12- | The theorist proposed this novel approach to enable safe agonism across disease | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-12-gap-debate-20260410-112812-429571d2 |
| sess_SDA-2026-04-12- | The debate revealed that no high-resolution structure exists for the critical hi | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-12-gap-debate-20260410-112837-d8c6fc48 |
| sess_SDA-2026-04-12- | The debate proposed bioenergetic gradients drive transfer but didn't identify th | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-12-gap-debate-20260410-112842-e2dec0d7 |
| sess_SDA-2026-04-16- | How does synaptic protein turnover change with age and neurodegeneration, and wh | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-16-frontier-proteomics-1c3dba72 |
| sess_SDA-2026-04-16- | What are the key metabolic alterations detectable in brain tissue, CSF, and bloo | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-16-frontier-metabolomics-f03b09d9 |
| sess_SDA-2026-04-16- | How does lipid metabolism dysregulation contribute to amyloidogenesis and tau pa | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-16-frontier-lipidomics-dcdbc360 |
| sess_SDA-2026-04-16- | How does chronic peripheral inflammation interact with CNS neuroimmune pathways | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-16-frontier-immunomics-e6f97b29 |
| sess_SDA-2026-04-16- | How does the human brain connectome reorganize in Alzheimer's disease, and what | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-16-frontier-connectomics-84acb35a |
| sess_SDA-2026-04-16- | There's a clear disconnect between improved mechanistic understanding of AD and | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-16-gap-pubmed-20260410-145418-c1527e7b |
| sess_SDA-2026-04-16- | What are the shared DNA methylation age acceleration and histone modification pa | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-16-gap-epigenetic-adpdals |
| sess_SDA-2026-04-16- | While RGS6 deficiency causes Parkinson's-like pathology, whether enhancing RGS6 | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-16-gap-pubmed-20260410-145520-5692b02e |
| sess_SDA-2026-04-17- | Analyze the spectrum of microglial activation states (DAM, homeostatic, inflamma | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-17-gap-20260416-220243 |
| sess_SDA-2026-04-17- | Analyze the spectrum of microglial activation states (DAM, homeostatic, inflamma | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-17-gap-microglial-subtypes-pharmaco-202604170000 |
| sess_SDA-2026-04-17- | While RGS6 deficiency causes Parkinson's-like pathology, whether enhancing RGS6 | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-2026-04-17-gap-pubmed-20260410-145520-5692b02e |
| sess_SDA-2026-04-17- | The fundamental premise remains unvalidated despite extensive mechanistic specul | 0.50 | 7 | 4 | completed | 2026-04-18 | SDA-2026-04-17-gap-debate-20260417-033037-c43d12c2 |
| sess_SDA-NEUROINFLAM | What is the optimal blood-based biomarker panel combining established markers (G | 0.50 | 0 | 4 | completed | 2026-04-18 | SDA-NEUROINFLAM-BIOMARKERPANEL-0b9129bc |
| sess_SDA-2026-04-18- | The debate highlighted compelling correlative evidence for ferroptosis markers i | 0.50 | 4 | 4 | completed | 2026-04-18 | SDA-2026-04-18-gap-debate-20260417-032952-48bdcbea |
| sess_SDA-2026-04-16- | The debate framework mentioned multiple microglial subtypes but no analysis was | 1.00 | 3 | 4 | completed | 2026-04-18 | SDA-2026-04-16-gap-debate-20260410-112642-fffdca96 |
| ds-SDA-2026-04-16-ga | Ferroptosis in ALS and motor neuron disease: GPX4, lipid peroxidation, and iron | 0.59 | 7 | 5 | completed | 2026-04-17 | SDA-2026-04-16-gap-ferroptosis-als-d2fb6bf796ed |
| DEBATE-BIOMNI-125926 | Is the gut microbiome a driver of PD pathology via SCFA depletion, or is dysbios | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-MICROBIO-337ee37a |
| DEBATE-BIOMNI-25ad6c | Does the hybrid DAM + interferon-response microglial population represent a nove | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-SCRNA_AN-248caecc |
| DEBATE-BIOMNI-f7eed7 | Is REST the master regulator of neuronal vulnerability in AD, or is it one of se | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-GENE_REG-785b71fe |
| DEBATE-BIOMNI-46c249 | Does fine-mapping to median 3-variant credible sets provide sufficient resolutio | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-FINE_MAP-215bc2c6 |
| DEBATE-BIOMNI-9892a9 | Does the BIN1 non-coding variant mechanism provide a druggable target, or is tra | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-VARIANT_-b5b8e32f |
| DEBATE-BIOMNI-0aafda | Are AD polygenic risk scores ready for clinical use in risk stratification, or d | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-POLYGENI-b3028c7a |
| DEBATE-BIOMNI-b0e2d2 | Is a 3-marker prognostic index clinically actionable for MCI patients, or does t | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-SURVIVAL-3e217f4d |
| DEBATE-BIOMNI-18feeb | Is the amyloid concentration in AD clinical trials rational given lecanemab's ap | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-CLINICAL-b7a71edd |
| DEBATE-BIOMNI-f2a534 | Is a 12-protein CSF panel superior to existing plasma p-tau217 for clinical AD p | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-PROTEOMI-c4a33049 |
| DEBATE-BIOMNI-33e7c0 | Is Cas13-based 4R-tau silencing feasible given collateral cleavage risks in post | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-CAS13_PR-d6f415f0 |
| DEBATE-BIOMNI-8a559d | Can computationally designed binders against alpha-synuclein realistically trans | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-BINDER_D-0657a9ed |
| DEBATE-BIOMNI-cedbd5 | Should clinical practice adopt multi-modal biomarker panels now, or wait for sin | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-BIOMARKE-34ec007c |
| DEBATE-BIOMNI-baf74a | Is the APOE-TREM2 communication axis a therapeutic target, or is disrupting it r | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-CELL_CEL-a7eed9c5 |
| DEBATE-BIOMNI-5b49bd | Is TYROBP a genuine therapeutic target in AD, or is it a downstream marker of mi | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-GENE_COE-55fc5237 |
| DEBATE-BIOMNI-aff2a8 | Do spatial transcriptomic neighborhoods provide sufficient discriminative power | 0.70 | 2 | 4 | completed | 2026-04-16 | SDA-BIOMNI-SPATIAL_-c2b61633 |
| sess_SDA-2026-04-16- | test | 0.65 | 0 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-20260416-133111 |
| sess_SDA-2026-04-16- | The abstract explicitly questions whether AD's hallmark pathologies induce choli | 0.95 | 7 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260411-082446-2c1c9e2d |
| sess_SDA-2026-04-16- | The abstract reports that Alectinib binds C1q with high affinity, but this is me | 0.94 | 7 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260410-095709-4e97c09e |
| sess_SDA-2026-04-04- | Investigate the therapeutic potential of clearing senescent cells (senolytics) t | 0.75 | 3 | 4 | completed | 2026-04-16 | SDA-2026-04-04-gap-senescent-clearance-neuro |
| sess_SDA-2026-04-16- | The skeptic raised evidence that APOE4 carriers show enhanced cholesterol synthe | 0.71 | 3 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-debate-20260410-113104-a13caf2e |
| sess_SDA-2026-04-16- | While the study establishes LRRK2 as a lysosomal swelling sensor and notes that | 0.85 | 3 | 4 | completed | 2026-04-16 | SDA-2026-04-16-gap-pubmed-20260410-170027-a1e5f867 |